Literature DB >> 33910877

Thrombotic Microangiopathy: A Rare Breast Cancer-associated Complication Treated Successfully With Doxorubicin and Cyclophosphamide.

Samuel Jalali1, Dakota Jenneman2, Ankita Tandon2, Hung Khong3.   

Abstract

BACKGROUND: Thrombotic microangiopathy (TMA) is a clinical syndrome consisting of hemolytic anemia, thrombocytopenia, and presence of schistocytes on peripheral blood smear secondary to disorders of systemic microvascular thrombosis. Malignancy-associated TMA is a rare entity and shares clinical features with that of HUS and TTP usually seen in patients with metastatic cancer, tumor cell infiltration of the bone marrow and/or response to cancer-directed therapy. CASE REPORT: We present a rare case of TMA secondary to breast cancer without evidence of bone marrow infiltration responsive to doxorubicin and cyclophosphamide treatment, after failed plasmapheresis with prednisone and later, eculizumab.
CONCLUSION: Despite being a rare manifestation of metastatic carcinoma, early identification and treatment are essential to improving survival. Copyright
© 2021, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Thrombotic microangiopathy; cancer; metastatic breast cancer; microangiopathic hemolytic anemia

Mesh:

Substances:

Year:  2021        PMID: 33910877      PMCID: PMC8193307          DOI: 10.21873/invivo.12452

Source DB:  PubMed          Journal:  In Vivo        ISSN: 0258-851X            Impact factor:   2.155


  14 in total

1.  Thrombotic microangiopathy associated with gemcitabine use: Presentation and outcome in a national French retrospective cohort.

Authors:  Florence Daviet; Franck Rouby; Pascale Poullin; Julie Moussi-Francès; Marion Sallée; Stéphane Burtey; Julien Mancini; Florence Duffaud; Renaud Sabatier; Bertrand Pourroy; Aurélie Grandvuillemin; Steven Grange; Véronique Frémeaux-Bacchi; Paul Coppo; Joëlle Micallef; Noémie Jourde-Chiche
Journal:  Br J Clin Pharmacol       Date:  2018-12-18       Impact factor: 4.335

2.  Microangiopathic haemolytic anaemia in metastasizing malignant tumours is not associated with a severe deficiency of the von Willebrand factor-cleaving protease.

Authors:  S Fontana; H E Gerritsen; J Kremer Hovinga; M Furlan; B Lämmle
Journal:  Br J Haematol       Date:  2001-04       Impact factor: 6.998

Review 3.  Systemic malignancies as a cause of unexpected microangiopathic hemolytic anemia and thrombocytopenia.

Authors:  James N George
Journal:  Oncology (Williston Park)       Date:  2011-09       Impact factor: 2.990

Review 4.  Cancer-related microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases.

Authors:  Klaus Lechner; Hanna Lena Obermeier
Journal:  Medicine (Baltimore)       Date:  2012-07       Impact factor: 1.889

5.  Microangiopathic hemolytic anemia in metastatic carcinoma. Report of eight cases.

Authors:  H P Lohrmann; W Adam; B Heymer; B Kubanek
Journal:  Ann Intern Med       Date:  1973-09       Impact factor: 25.391

6.  How I treat patients with thrombotic thrombocytopenic purpura: 2010.

Authors:  James N George
Journal:  Blood       Date:  2010-08-04       Impact factor: 22.113

7.  Breast Cancer-Associated Thrombotic Microangiopathy.

Authors:  Anne C Regierer; Dagmar Kuehnhardt; Carsten-Oliver Schulz; Bernd Flath; Christian F Jehn; Christian W Scholz; Kurt Possinger; Jan Eucker
Journal:  Breast Care (Basel)       Date:  2011-12-15       Impact factor: 2.860

Review 8.  Microangiopathic Hemolytic Anemia and Thrombocytopenia in Patients With Cancer.

Authors:  Jordan M Morton; James N George
Journal:  J Oncol Pract       Date:  2016-06       Impact factor: 3.840

9.  Microangiopathic hemolytic anemia associated with metastatic breast cancer: case report and literature review.

Authors:  Daisuke Takabatake; Kazuyuki Oishi
Journal:  Springerplus       Date:  2016-05-20

10.  Hemolytic Anemia of Malignancy: A Case Study Involving Signet Ring Cell Metastatic Breast Cancer with Severe Microangiopathic Hemolytic Anemia.

Authors:  Eric H Lee; Salman Otoukesh; Amir Abdi Pour; Gayathri Nagaraj
Journal:  Case Rep Oncol       Date:  2019-01-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.